We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial.
- Authors
Gelbenegger, Georg; Jaeger, Ulrich; Fillitz, Michael; D'Sa, Shirley; Cartwright, Ronwyn; Shafer, Frank; Wardecki, Marek; Wang, Jennifer; Schoergenhofer, Christian; Jilma, Bernd
- Abstract
Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia (AIHA), which leads to fatigue and acrocyanosis.1-4 Until recently, treatment of CAD was mainly based on reduction of the B-cell clone by rituximab or chemo-immunotherapy. In patients 1 and 2, sutimlimab abrogated complement-mediated haemolysis, which resulted in peak haemoglobin levels of >120 g/L. Some residual haemolysis, as measured by undetectable haptoglobin levels, was observed in patients 3 and 4 (Figure S1). Patient 1: 6 weeks, Patient 2: 47 weeks, Patient 3: 6 weeks, Patient 4: 6 weeks.
- Subjects
WALDENSTROM'S macroglobulinemia; RED blood cell transfusion; AUTOIMMUNE hemolytic anemia
- Publication
British Journal of Haematology, 2022, Vol 198, Issue 4, pe59
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.18289